Blogs

Researchers zero in on new class of oral cancer drugs

Researchers zero in on new class of oral cancer drugs

Novel agents have potential to break 40-year drought in oral cancer drug development SAN ANTONIO ...

November 05, 2025

View Details
San Antonio researchers check synthetic version of capsaicin — the heat in chile peppers — for cancer-killing effects

San Antonio researchers check synthetic version of capsai...

But the properties of capsaicin could have a deeper significance. The relationship between pain a...

November 05, 2025

View Details
UT Health San Antonio School of Dentistry researcher and her company earn Small Business Technology Transfer grant

UT Health San Antonio School of Dentistry researcher and ...

SAN ANTONIO, Jan. 30, 2025 – A UT Health San Antonio School of Dentistry researcher and her pione...

November 05, 2025

View Details
Inhibition of Ca2+ entry by capsazepine analog CIDD-99 prevents oral squamous carcinoma cell proliferation

Inhibition of Ca2+ entry by capsazepine analog CIDD-99 pr...

Oral cancer patients have a poor prognosis, with approximately 66% of patients surviving 5-years ...

November 05, 2025

View Details
The Novel Capsazepine Analog, CIDD-99, Significantly Inhibits Oral Squamous Cell Carcinoma In Vivo Through a TRPV1-Independent Induction of ER Stress, Mitochondrial Dysfunction, and Apoptosis

The Novel Capsazepine Analog, CIDD-99, Significantly Inhi...

Oral squamous cell carcinoma (OSCC) is a deadly disease with a mere 40% five-year survival rate f...

November 05, 2025

View Details

Awards:

Award Logo Award Logo Award Logo Award Logo Award Logo

Connect

Email cara@keraceuticals.net

Contact Us